trimethoprim has been researched along with Cystic Fibrosis of Pancreas in 27 studies
Trimethoprim: A pyrimidine inhibitor of dihydrofolate reductase, it is an antibacterial related to PYRIMETHAMINE. It is potentiated by SULFONAMIDES and the TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION is the form most often used. It is sometimes used alone as an antimalarial. TRIMETHOPRIM RESISTANCE has been reported.
trimethoprim : An aminopyrimidine antibiotic whose structure consists of pyrimidine 2,4-diamine and 1,2,3-trimethoxybenzene moieties linked by a methylene bridge.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The disposition of sulfamethoxazole and trimethoprim, after constant rate intravenous administration (10 mg/kg/hr sulfamethoxazole and 2 mg/kg/hr trimethoprim for 1 hour), was investigated in adult patients with cystic fibrosis (n = 7) and in age-matched healthy subjects (control subjects, n = 8)." | 7.68 | Disposition of drugs in cystic fibrosis. I. Sulfamethoxazole and trimethoprim. ( Hutabarat, RM; McNamara, S; Ramsey, B; Sahajwalla, C; Smith, AL; Unadkat, JD, 1991) |
| "The first-dose and steady-state pharmacokinetics of trimethoprim and sulfamethoxazole were determined in 14 patients with cystic fibrosis." | 7.67 | Dosing implications of rapid elimination of trimethoprim-sulfamethoxazole in patients with cystic fibrosis. ( Bertino, JS; Blumer, JL; Myers, CM; Reed, MD; Stern, RC; Yamashita, TS, 1984) |
| "During a 1-year period, the prevalence of thymidine-dependent (TD) Staphylococcus aureus in patients at two geographically distinct cystic fibrosis (CF) centers was determined." | 7.67 | Prevalence of thymidine-dependent Staphylococcus aureus in patients with cystic fibrosis. ( Gage, PA; Gilligan, PH; Muszynski, MJ; Wait, KR; Welch, DF, 1987) |
| "The disposition of sulfamethoxazole and trimethoprim, after constant rate intravenous administration (10 mg/kg/hr sulfamethoxazole and 2 mg/kg/hr trimethoprim for 1 hour), was investigated in adult patients with cystic fibrosis (n = 7) and in age-matched healthy subjects (control subjects, n = 8)." | 3.68 | Disposition of drugs in cystic fibrosis. I. Sulfamethoxazole and trimethoprim. ( Hutabarat, RM; McNamara, S; Ramsey, B; Sahajwalla, C; Smith, AL; Unadkat, JD, 1991) |
| "The first-dose and steady-state pharmacokinetics of trimethoprim and sulfamethoxazole were determined in 14 patients with cystic fibrosis." | 3.67 | Dosing implications of rapid elimination of trimethoprim-sulfamethoxazole in patients with cystic fibrosis. ( Bertino, JS; Blumer, JL; Myers, CM; Reed, MD; Stern, RC; Yamashita, TS, 1984) |
| "During a 1-year period, the prevalence of thymidine-dependent (TD) Staphylococcus aureus in patients at two geographically distinct cystic fibrosis (CF) centers was determined." | 3.67 | Prevalence of thymidine-dependent Staphylococcus aureus in patients with cystic fibrosis. ( Gage, PA; Gilligan, PH; Muszynski, MJ; Wait, KR; Welch, DF, 1987) |
| "Ciprofloxacin MICs were 0." | 1.30 | In-vitro investigation of the antibacterial activity of agents which may be used for the oral treatment of lung infections in CF patients. ( Hamilton, VE; Richards, RM; Thomas, MR, 1998) |
| "Inadequate therapeutic results in the treatment of bacterial infections in patients with Cystic Fibrosis prompted a reevaluation of pharmacokinetic parameters of orally and parenterally administered drugs in these patients." | 1.26 | [Pharmacokinetic of antibiotics in patients with mucoviscidosis (author's transl)]. ( Guggenbichler, JP; Pillwein, K; Rohrer, R; Schabel, F, 1981) |
| "The same applies for mucoviscidosis, in which P." | 1.26 | [Therapy of chronic respiratory tract infections in children, including mucoviscidosis (author's transl)]. ( Adam, D, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 16 (59.26) | 18.7374 |
| 1990's | 3 (11.11) | 18.2507 |
| 2000's | 2 (7.41) | 29.6817 |
| 2010's | 2 (7.41) | 24.3611 |
| 2020's | 4 (14.81) | 2.80 |
| Authors | Studies |
|---|---|
| Chung, WJ | 1 |
| Goeckeler-Fried, JL | 1 |
| Havasi, V | 1 |
| Chiang, A | 1 |
| Rowe, SM | 1 |
| Plyler, ZE | 1 |
| Hong, JS | 1 |
| Mazur, M | 1 |
| Piazza, GA | 1 |
| Keeton, AB | 1 |
| White, EL | 1 |
| Rasmussen, L | 1 |
| Weissman, AM | 1 |
| Denny, RA | 1 |
| Brodsky, JL | 1 |
| Sorscher, EJ | 1 |
| Chang, TH | 1 |
| Chuang, YC | 1 |
| Wang, JT | 1 |
| Sheng, WH | 1 |
| Jaiyesimi, OA | 1 |
| McAvoy, AC | 2 |
| Fogg, DN | 1 |
| Garg, N | 2 |
| Jaiyesimi, O | 1 |
| Threatt, PH | 1 |
| Seladi, T | 1 |
| Goldberg, JB | 1 |
| da Silva, RR | 1 |
| Jones, C | 1 |
| Webster, G | 1 |
| Mullins, AJ | 1 |
| Jenner, M | 1 |
| Bull, MJ | 1 |
| Dashti, Y | 1 |
| Spilker, T | 1 |
| Parkhill, J | 1 |
| Connor, TR | 1 |
| LiPuma, JJ | 1 |
| Challis, GL | 1 |
| Mahenthiralingam, E | 1 |
| Van Dalem, A | 1 |
| Herpol, M | 1 |
| Echahidi, F | 1 |
| Peeters, C | 1 |
| Wybo, I | 1 |
| De Wachter, E | 1 |
| Vandamme, P | 1 |
| Piérard, D | 1 |
| Tomlin, KL | 1 |
| Clark, SR | 1 |
| Ceri, H | 1 |
| Petersen, BE | 1 |
| Jenkins, SG | 1 |
| Yuan, S | 1 |
| Lamm, C | 1 |
| Szporn, AH | 1 |
| Marks, MI | 1 |
| Gold, R | 1 |
| Jin, E | 1 |
| Levison, H | 1 |
| Isles, A | 1 |
| Fleming, PC | 1 |
| Reed, MD | 1 |
| Stern, RC | 1 |
| Bertino, JS | 1 |
| Myers, CM | 1 |
| Yamashita, TS | 1 |
| Blumer, JL | 1 |
| Huang, NN | 2 |
| Schidlow, DV | 1 |
| Palmer, JJ | 1 |
| Antonelli, M | 1 |
| De Angelis, M | 1 |
| Bravo, E | 1 |
| Lorusso, G | 1 |
| Ascalone, V | 1 |
| Guggenbichler, JP | 1 |
| Pillwein, K | 1 |
| Schabel, F | 1 |
| Rohrer, R | 1 |
| Middleton, PG | 1 |
| Geddes, DM | 1 |
| Alton, EW | 1 |
| Richards, RM | 1 |
| Hamilton, VE | 1 |
| Thomas, MR | 1 |
| Sparham, PD | 1 |
| Lobban, DI | 1 |
| Speller, DC | 1 |
| Adam, D | 1 |
| Hughes, DT | 1 |
| Pines, A | 1 |
| Percival, A | 1 |
| Stille, W | 1 |
| Quietzsch, J | 1 |
| Siegert, E | 1 |
| Günther, J | 1 |
| Parsons, RL | 1 |
| Paddock, GM | 1 |
| Hutabarat, RM | 1 |
| Unadkat, JD | 1 |
| Sahajwalla, C | 1 |
| McNamara, S | 1 |
| Ramsey, B | 1 |
| Smith, AL | 1 |
| Kuriyama, S | 1 |
| Panosian, C | 1 |
| Lapointe, JR | 1 |
| Bourget, C | 1 |
| Lafleur, L | 1 |
| Lagacé, J | 1 |
| Montplaisir, S | 1 |
| Gilligan, PH | 1 |
| Gage, PA | 1 |
| Welch, DF | 1 |
| Muszynski, MJ | 1 |
| Wait, KR | 1 |
| Rawal, BD | 1 |
| McKay, G | 1 |
| Blackhall, MI | 1 |
2 reviews available for trimethoprim and Cystic Fibrosis of Pancreas
| Article | Year |
|---|---|
Antibiotics in pediatric respiratory diseases.
Topics: Aminoglycosides; Anti-Bacterial Agents; Cephalosporins; Child; Chloramphenicol; Cystic Fibrosis; Emp | 1980 |
Respiratory pharmacology. Antibiotics. II. Aminoglycosides, polymyxins, vancomycin, trimethoprim-sulfamethoxazole, and pentamidine.
Topics: Aminoglycosides; Anti-Bacterial Agents; Cystic Fibrosis; Drug Combinations; Drug Resistance, Microbi | 1986 |
25 other studies available for trimethoprim and Cystic Fibrosis of Pancreas
| Article | Year |
|---|---|
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regu | 2016 |
Clinical characteristics and outcomes of non-cystic fibrosis patients with Burkholderia cepacia complex bacteremia at a medical center in Taiwan.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacteremia; Burkholderia cepacia; Burkholderia cepacia complex; | 2022 |
Metabolomic profiling of Burkholderia cenocepacia in synthetic cystic fibrosis sputum medium reveals nutrient environment-specific production of virulence factors.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Burkholderia cenocepacia; Burkholderia Infections; Chroma | 2021 |
Differences in Cystic Fibrosis-Associated
Topics: Anti-Bacterial Agents; Burkholderia; Burkholderia Infections; Cystic Fibrosis; Humans; Metabolome; T | 2020 |
Kill and cure: genomic phylogeny and bioactivity of
Topics: Biosynthetic Pathways; Bongkrekic Acid; Burkholderia gladioli; Cystic Fibrosis; Food Microbiology; H | 2021 |
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Burkholderia cepacia complex; Ceftazidime; Cephalospori | 2018 |
Green and red fluorescent protein vectors for use in biofilm studies of the intrinsically resistant Burkholderia cepacia complex.
Topics: Anti-Infective Agents; Biofilms; Burkholderia cepacia complex; Cystic Fibrosis; Genetic Vectors; Gre | 2004 |
Nocardia farcinica isolated from bronchoalveolar lavage fluid of a child with cystic fibrosis.
Topics: Anti-Infective Agents; Bronchoalveolar Lavage; Child; Cystic Fibrosis; Drug Combinations; Humans; Ma | 2007 |
Treatment of cystic fibrosis with trimethoprim-sulfamethoxazole.
Topics: Cystic Fibrosis; Drug Combinations; Humans; Sulfamethoxazole; Trimethoprim; Trimethoprim, Sulfametho | 1984 |
Ceftazidime alone and in combination in patients with cystic fibrosis: lack of efficacy in treatment of severe respiratory infections caused by Pseudomonas cepacia.
Topics: Adolescent; Ceftazidime; Cephalosporins; Cystic Fibrosis; Drug Combinations; Drug Therapy, Combinati | 1983 |
Dosing implications of rapid elimination of trimethoprim-sulfamethoxazole in patients with cystic fibrosis.
Topics: Adolescent; Adult; Cystic Fibrosis; Dose-Response Relationship, Drug; Drug Combinations; Drug Synerg | 1984 |
[Absorption of orally-administered cotrimoxazole in patients with cystic fibrosis].
Topics: Child; Child, Preschool; Cystic Fibrosis; Drug Combinations; Humans; Intestinal Absorption; Sulfamet | 1982 |
[Pharmacokinetic of antibiotics in patients with mucoviscidosis (author's transl)].
Topics: Adolescent; Adult; Anti-Bacterial Agents; Azlocillin; Child; Cystic Fibrosis; Gentamicins; Humans; M | 1981 |
Trimethoprim and tetracycline inhibit airway epithelial sodium absorption.
Topics: Absorption; Adult; Amiloride; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Cystic Fibrosis | 1996 |
In-vitro investigation of the antibacterial activity of agents which may be used for the oral treatment of lung infections in CF patients.
Topics: Administration, Oral; Anti-Bacterial Agents; Ciprofloxacin; Cystic Fibrosis; Drug Therapy, Combinati | 1998 |
Thymidine-requiring Staphylococcus aureus.
Topics: Cystic Fibrosis; Drug Resistance, Microbial; Humans; Staphylococcus aureus; Thymidine; Trimethoprim | 1978 |
[Therapy of chronic respiratory tract infections in children, including mucoviscidosis (author's transl)].
Topics: Cephalosporins; Child; Child, Preschool; Cystic Fibrosis; Drug Combinations; Humans; Infant; Infant, | 1979 |
Round table discussion--treatment of lower respiratory tract infections with co-trimoxazole.
Topics: Bronchiectasis; Bronchitis; Chronic Disease; Cystic Fibrosis; Drug Combinations; Humans; Lung Absces | 1979 |
[Multilobular biliary liver cirrhosis as a purely hepatic form of mucoviscidosis].
Topics: Child; Cholangitis; Cholecystitis; Cystic Fibrosis; Drug Combinations; Humans; Liver Cirrhosis; Male | 1979 |
The use of new antibiotic agents for chronic pulmonary disease.
Topics: Agammaglobulinemia; Aminoglycosides; Anti-Bacterial Agents; Asthma; Bacterial Infections; Cephalospo | 1978 |
Absorption of two antibacterial drugs, cephalexin and co-trimoxazole, in malabsorption syndromes.
Topics: Celiac Disease; Cephalexin; Cholestyramine Resin; Crohn Disease; Cystic Fibrosis; Diverticulum; Drug | 1975 |
Disposition of drugs in cystic fibrosis. I. Sulfamethoxazole and trimethoprim.
Topics: Adult; Chromatography, High Pressure Liquid; Cystic Fibrosis; Female; Humans; Male; Metabolic Cleara | 1991 |
Mucoid and pigmentation characters can be suppressed by non-anti-Pseudomonas aeruginosa antibiotics in cystic fibrosis: a report of promising preliminary results.
Topics: Anti-Bacterial Agents; Cystic Fibrosis; Doxycycline; Drug Combinations; Humans; Leucomycins; Pigment | 1988 |
Prevalence of thymidine-dependent Staphylococcus aureus in patients with cystic fibrosis.
Topics: Culture Media; Cystic Fibrosis; Drug Combinations; Humans; Respiratory System; Staphylococcus aureus | 1987 |
Inhibition of Pseudomonas aeruginosa by ascorbic acid acting singly and in combination with antimicrobials: in-vitro and in-vivo studies.
Topics: Adolescent; Animals; Anti-Bacterial Agents; Ascorbic Acid; Child; Cystic Fibrosis; Drug Combinations | 1974 |